Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Therapeutic modalities targeting TREX1 can activate cGAS-STING signaling and can be incorporated into autologous cancer vaccine designs to improve cancer treatment, supporting the potential of inactivating TREX1 to harness innate immunity. See related commentary by Hanks, p. 2778.
Authors
- Nicole Dobbs (ORCID: https://orcid.org/0000-0003-1944-9740)
- Cong Xing (ORCID: https://orcid.org/0000-0001-9641-335X)
- Xintao Tu (ORCID: https://orcid.org/0000-0001-8789-5297)
- Devon Jeltema (ORCID: https://orcid.org/0000-0002-5338-3477)
- Kun Yang (ORCID: https://orcid.org/0000-0002-2011-7084)
- Wanwan Huai (ORCID: https://orcid.org/0000-0002-6709-3315)
- Nan Yan (ORCID: https://orcid.org/0000-0002-0637-3989)
- Zhen Tang (ORCID: https://orcid.org/0000-0001-8008-9428)
- Kennady Knox (ORCID: https://orcid.org/0000-0003-3874-1691)
- Kun Song (ORCID: https://orcid.org/0009-0008-6658-0980)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1158/0008-5472.can-24-2747
- Citations
- 10
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 7.97
Funders
- Cancer Prevention and Research Institute of Texas
- National Institute of Allergy and Infectious Diseases